1 January 2019 in Clinical Gastroenterology and Hepatology
1 August 2019 in Clinical Gastroenterology and Hepatology
31 August 2017 in Hepatology
18 February 2022 in Clinical Gastroenterology and Hepatology
26 June 2017 in Liver Transplantation
Liver transplantation (LT) is a well‐established treatment for hepatocellular carcinoma (HCC) in carefully selected patients. Risk factors for tumors with poor prognostic features on explant have not been well described in a national cohort. We performed a retrospective cohort study of adult LT recipients with HCC transplanted from April 8, 2012 (when explant pathology in United Network for Organ Sharing [UNOS] became available) until September 30, 2014. We evaluated the association between listing diagnosis and other demographic factors with tumor features on explant using logistic regression. High‐risk tumor features included the following: > 3 tumors, largest tumor > 5 cm, presence of vascular invasion, presence of metastases, and poor differentiation of tumor. In total, 3733 LT recipients with HCC who had complete explant data in UNOS were included. The median age was 60 years; 78% were male; and 68% were white. Of the primary non‐HCC listing diagnoses, 2608 (70%) had hepatitis C virus (HCV); 271 (7%) had nonalcoholic steatohepatitis (NASH); 246 (7%) had alcoholic cirrhosis; and 189 (5%) had hepatitis B virus. Also, 1140 (31%) had evidence of ≥ 1 high‐risk explant feature(s). The presence of ≥ 1 high‐risk explant feature(s) was associated with HCC recurrence after transplant (odds ratio [OR], 5.00; P < 0.001). Compared with HCV‐associated HCC transplant recipients, individuals with NASH had lower likelihood of high‐risk explant features (OR, 0.71; P = 0.02) after adjusting for covariables. Women were more likely to have high‐risk explant features (OR, 1.23; P = 0.04). Diabetes mellitus (DM) was not associated with high‐risk explant features. In conclusion, LT recipients with NASH‐associated HCC had fewer high‐risk tumor features on explant compared with HCV‐associated HCC, despite having higher rates of DM and other potential risk factors for the development of HCC. Women had a higher likelihood of high‐risk tumor features. Further study is warranted whether these differences are due to disease‐specific or sex‐specific influences on tumor biology or due to selection criteria for transplant. Liver Transplantation 23 1015–1022 2017 AASLD.
3 January 2023 in Liver Transplantation
Sarcopenic obesity is associated with higher rates of morbidity and mortality than seen with either sarcopenia or obesity alone. We aimed to define sarcopenic visceral obesity (SVO) using CT-quantified skeletal muscle index and visceral-to-subcutaneous adipose tissue ratio and to examine its association with waitlist mortality in patients with cirrhosis. Included were 326 adults with cirrhosis awaiting liver transplantation in the ambulatory setting with available abdominal CT within 6 months from enrollment between February 2015 and January 2018. SVO was defined as patients with sarcopenia (skeletal muscle index <50 cm2/m2 in men and <39 cm2/m2 in women) and visceral obesity (visceral-to-subcutaneous adipose tissue ratio ≥1.21 in men and ≥0.48 in women). The percentage who met criteria for sarcopenia, visceral obesity, and SVO were 44%, 29%, and 13%, respectively. Cumulative incidence of waitlist mortality was higher in patients with SVO compared to patients with sarcopenia without visceral obesity or visceral obesity without sarcopenia at 12 months (40% vs. 21% vs. 12%) (overall logrank p=0.003). In univariable Cox regression, SVO was associated with waitlist mortality (HR: 3.42, 95% CI: 1.58–7.39), which remained significant after adjusting for age, sex, diabetes, ascites, encephalopathy, MELDNa, liver frailty index, and different body compositions (HR: 2.64, 95% CI: 1.11–6.30). SVO was associated with increase waitlist mortality in patients with cirrhosis in the ambulatory setting awaiting liver transplantation. Concurrent loss of skeletal muscle and gain of adipose tissue seen in SVO quantified by CT may be a useful and objective measurement to identify patients at risk for suboptimal pretransplant outcomes.